{"id":22965,"date":"2020-03-24T20:42:26","date_gmt":"2020-03-25T03:42:26","guid":{"rendered":"https:\/\/lapost.us\/?p=22965"},"modified":"2020-03-24T20:42:26","modified_gmt":"2020-03-25T03:42:26","slug":"mesa-biotech-gets-emergency-fda-approval-for-rapid-covid-19-testing","status":"publish","type":"post","link":"https:\/\/lapost.us\/?p=22965","title":{"rendered":"Mesa Biotech gets emergency FDA approval for rapid COVID-19 testing"},"content":{"rendered":"<h3 id=\"yui_3_17_2_1_1585107725109_332\"><em id=\"yui_3_17_2_1_1585107725109_331\">Easy to use, palm-sized system will enable broader use across healthcare facilities closer to the patients and will begin shipping immediately<\/em><\/h3>\n<p class=\"\"><strong>SAN DIEGO, CA<\/strong> \u2013 March 24, 2020 \u2013 Today, Mesa Biotech announced it has received Emergency Use Authorization (EUA) from the U.S. Food &amp; Drug Administration (FDA) for its Accula\u2122 SARS-CoV-2 Test, which gives COVID-19 diagnostic results in 30 minutes. Mesa Biotech Inc., a privately-held, molecular diagnostic company has developed an affordable, easy to use, testing platform designed for point-of-care (POC) infectious disease diagnosis. The COVID-19 test uses this patented technology to enable \u2018near patient\u2019 testing allowing testing outside of the central laboratory.<\/p>\n<p class=\"\">\u201cMesa is excited to immediately begin shipping our rapid, molecular SARS-CoV-2 test so people can get answers in 30 minutes. Our Accula system is easy to use and fits in the palm of your hand. This allows many units to be run side by side in the doctor\u2019s office further increasing the speed of COVID-19 diagnosis. Accula provides a true decentralized testing solution for COVID-19 at the point of care,\u201d said Hong Cai, Co-founder and Chief Executive Officer, Mesa Biotech, Inc. \u201cOur test will provide a highly accessible means for healthcare professionals to access laboratory quality results close in their office to aid in the decision to isolate, treat or dismiss potential carriers of the virus. The potential to reduce the growing strain on our nation\u2019s hospitals is tremendous.\u201d<\/p>\n<p class=\"\">The Accula SARS-CoV-2 Test is a visually read test using polymerase chain reaction (PCR) technology to detect SARS-CoV-2 (the virus responsible for COVID-19) via throat and nasal swab samples. Similar to Mesa Biotech\u2019s commercially available tests for influenza and RSV, the Accula SARS-CoV-2 Test is designed for the point-of-care use, including temporary screening facilities, physician office labs, urgent care, and long term nursing facilities. The system complements central laboratories where current testing is performed. Mesa Biotech\u2019s compact coronavirus test yields laboratory-quality results in approximately 30 minutes.<\/p>\n<p class=\"\">Mesa Biotech\u2019s technology was developed at Los Alamos National Lab supported by NIH grants from the National Institute of Allergy and Infectious Diseases (NIAID) and the Western Regional Centers for Excellence in Biodefense and Emerging Infectious Disease program. Last week, the company received funding from the U.S. Health and Human Services for development of its SARS-CoV-2 test. Since its inception, the company has focused on technology well-suited for emergency defense and rapid deployment for SARS, Ebola and other emerging infectious diseases. Mesa Biotech\u2019s platform was specifically designed for use outside the lab to enable rapid responses to global pandemics, such as COVID-19.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Easy to use, palm-sized system will&#46;&#46;&#46;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6,16,7],"tags":[],"class_list":["post-22965","post","type-post","status-publish","format-standard","hentry","category-ca-local","category-health","category-u-s-a"],"_links":{"self":[{"href":"https:\/\/lapost.us\/index.php?rest_route=\/wp\/v2\/posts\/22965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lapost.us\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lapost.us\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lapost.us\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lapost.us\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22965"}],"version-history":[{"count":1,"href":"https:\/\/lapost.us\/index.php?rest_route=\/wp\/v2\/posts\/22965\/revisions"}],"predecessor-version":[{"id":22966,"href":"https:\/\/lapost.us\/index.php?rest_route=\/wp\/v2\/posts\/22965\/revisions\/22966"}],"wp:attachment":[{"href":"https:\/\/lapost.us\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lapost.us\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lapost.us\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}